Target selection issues in drug discovery and development.
Targets for cancer treatments have been proposed which address oncogenes mutated in tumors (pathogenic targets). Yet additional opportunities may come from molecules expressed in the tissue of origin (ontogenic); allow drug handling (pharmacological) or address the tumor microenvironment. The key is to define an assay that defines a therapeutic index which can be achieved in modulated target function.
Sausville
E A
EA
Developmental Therapeutics Program, National Cancer Institute, Bethesda, MD, USA. esausville@umm.edu
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D004195:Disease Models, Animal; D016503:Drug Delivery Systems; D015195:Drug Design; D004354:Drug Screening Assays, Antitumor; D005260:Female; D005544:Forecasting; D018390:Gene Targeting; D015894:Genome, Human; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D012680:Sensitivity and Specificity; D014481:United States
D000970:Antineoplastic Agents